Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
7(64%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_1
2
18%
Ph phase_4
1
9%
Ph phase_3
8
73%

Phase Distribution

2

Early Stage

0

Mid Stage

9

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 3Large-scale testing
8(72.7%)
Phase 4Post-market surveillance
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

11

all time

Status Distribution
Active(9)
Completed(2)

Detailed Status

Recruiting6
Not yet recruiting2
Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
7
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 38 (72.7%)
Phase 41 (9.1%)

Trials by Status

active_not_recruiting19%
not_yet_recruiting218%
recruiting655%
completed218%

Recent Activity

7 active trials
Showing 5 of 11
recruitingphase_3

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

NCT05334368
recruitingphase_3

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339
not_yet_recruitingphase_4

Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

NCT07701967
active_not_recruitingphase_3

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934
recruitingphase_3

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

NCT06979323
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05334368Phase 3

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

Recruiting
NCT07177339Phase 3

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

Recruiting
NCT07701967Phase 4

Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Not Yet Recruiting
NCT05263934Phase 3

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Active Not Recruiting
NCT06979323Phase 3

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

Recruiting
NCT07671001Phase 3

A Study of Depemokimab in Participants of 6 to 11 Years of Age

Not Yet Recruiting
NCT07456033Phase 3

A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

Recruiting
NCT05602025Phase 1

A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants

Completed
NCT05140200Phase 1

Study of GSK3511294 in Healthy Chinese Participants

Completed
NCT06961214Phase 3

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

Recruiting
NCT06959095Phase 3

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

Recruiting

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11